International audienceThe European Union Committee of Experts on Rare Diseases was entrusted with aiding the European Commission in a number of tasks, ranging from the monitoring of initiatives, to recommending improvements and actions to be pursued in the future, in addition to helping strengthen liaison at both European and International levels in the field of rare diseases. The three-year mandate of the EUCERD drew to a close in July 2013 with an impressive record. The EUCERD has laid down the foundations for future work so as to continue to advance in the key areas that have been identified as of interest for the rare disease community at large: centres of expertise, European Reference Networks, patient registries and databases, newborn...
Biobanking is of high importance for research in rare diseases. There are >6,000 rare dise...
The low incidence and the heterogeneity of very rare tumors (VRTs) demand for international cooperat...
National Rare Disease Plan for Ireland 2014-2018 This is a generic policy framework for rare disease...
International audienceThe European Union Committee of Experts on Rare Diseases was entrusted with ai...
Two years ago, at the ECRD in Krakow, we were celebrat-ing the recommendation of the Council of Mini...
The development of centres of expertise (CE) and European Reference Networks (ERN) in the field of r...
International audienceAround 4% of the global population suffers from a rare disease. Apart from the...
This IPH report (2013) (prepared for the ROI Department of Health) presents findings from the Nation...
AbstractRare diseases are those with a particularly low prevalence; in Europe, diseases are consider...
© 2017 European Society of Human Genetics. The International Rare Diseases Research Consortium (IRDi...
New challenges and priorities are given in the EU Health programme 2007-2013. The objectives of the ...
RARE-Bestpractices (http://www.rarebestpractices.eu) is a 4-year project (2013-2016) funded by the E...
In 2009 the European Commission asked the Member States to develop a strategy to improve the care of...
Altres ajuts: This work and the IRDiRC Scientific Secretariat are supported by the European FP7 cont...
International audienceBACKGROUND:Although rare disease patients make up approximately 6-8% of all pa...
Biobanking is of high importance for research in rare diseases. There are >6,000 rare dise...
The low incidence and the heterogeneity of very rare tumors (VRTs) demand for international cooperat...
National Rare Disease Plan for Ireland 2014-2018 This is a generic policy framework for rare disease...
International audienceThe European Union Committee of Experts on Rare Diseases was entrusted with ai...
Two years ago, at the ECRD in Krakow, we were celebrat-ing the recommendation of the Council of Mini...
The development of centres of expertise (CE) and European Reference Networks (ERN) in the field of r...
International audienceAround 4% of the global population suffers from a rare disease. Apart from the...
This IPH report (2013) (prepared for the ROI Department of Health) presents findings from the Nation...
AbstractRare diseases are those with a particularly low prevalence; in Europe, diseases are consider...
© 2017 European Society of Human Genetics. The International Rare Diseases Research Consortium (IRDi...
New challenges and priorities are given in the EU Health programme 2007-2013. The objectives of the ...
RARE-Bestpractices (http://www.rarebestpractices.eu) is a 4-year project (2013-2016) funded by the E...
In 2009 the European Commission asked the Member States to develop a strategy to improve the care of...
Altres ajuts: This work and the IRDiRC Scientific Secretariat are supported by the European FP7 cont...
International audienceBACKGROUND:Although rare disease patients make up approximately 6-8% of all pa...
Biobanking is of high importance for research in rare diseases. There are >6,000 rare dise...
The low incidence and the heterogeneity of very rare tumors (VRTs) demand for international cooperat...
National Rare Disease Plan for Ireland 2014-2018 This is a generic policy framework for rare disease...